63PReal-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients

63PReal-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2019-04, Vol.30 (Supplement_2)
Hauptverfasser: Hochmair, M J, Weinlinger, C, Fabikan, H, Koger, R, Krenbeck, D, Huemer, F, Illini, O M, Kulaksiz, M, Valipour, A, Burghuber, O C
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_2
container_start_page
container_title Annals of oncology
container_volume 30
creator Hochmair, M J
Weinlinger, C
Fabikan, H
Koger, R
Krenbeck, D
Huemer, F
Illini, O M
Kulaksiz, M
Valipour, A
Burghuber, O C
description
doi_str_mv 10.1093/annonc/mdz071.003
format Article
fullrecord <record><control><sourceid>oup</sourceid><recordid>TN_cdi_oup_primary_10_1093_annonc_mdz071_003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdz071.003</oup_id><sourcerecordid>10.1093/annonc/mdz071.003</sourcerecordid><originalsourceid>FETCH-oup_primary_10_1093_annonc_mdz071_0033</originalsourceid><addsrcrecordid>eNqVkEFOwzAQRS0EEqFwAHZzANLadZuSdQCxyAJR9pbbTMggxzG2U2gPw1lJGy7Aajbv_ZEeY7eCTwXP5Uxb29ntrK0OfCWmnMszlohllqf3fCHOWcLzuUxXS7m4ZFchfHDOs3yeJ-wnky-vqE1qqEbAb4ee0G4Rvig2EBsEap3BFm3UkToLXQ0PZSkhRE2W7DtoW5240G8CfvYDCNGjjkdlXPHdThtHsT_0rd5AxECe7LBsoUG9I7MH5_EkYQXroizADc8GP1yzi1qbgDd_d8Lunh7fiue0651ynlrt90pwdWygxgZqbKCGBvKf-C8-Amq1</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>63PReal-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients</title><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Hochmair, M J ; Weinlinger, C ; Fabikan, H ; Koger, R ; Krenbeck, D ; Huemer, F ; Illini, O M ; Kulaksiz, M ; Valipour, A ; Burghuber, O C</creator><creatorcontrib>Hochmair, M J ; Weinlinger, C ; Fabikan, H ; Koger, R ; Krenbeck, D ; Huemer, F ; Illini, O M ; Kulaksiz, M ; Valipour, A ; Burghuber, O C</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdz071.003</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Annals of oncology, 2019-04, Vol.30 (Supplement_2)</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids></links><search><creatorcontrib>Hochmair, M J</creatorcontrib><creatorcontrib>Weinlinger, C</creatorcontrib><creatorcontrib>Fabikan, H</creatorcontrib><creatorcontrib>Koger, R</creatorcontrib><creatorcontrib>Krenbeck, D</creatorcontrib><creatorcontrib>Huemer, F</creatorcontrib><creatorcontrib>Illini, O M</creatorcontrib><creatorcontrib>Kulaksiz, M</creatorcontrib><creatorcontrib>Valipour, A</creatorcontrib><creatorcontrib>Burghuber, O C</creatorcontrib><title>63PReal-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVkEFOwzAQRS0EEqFwAHZzANLadZuSdQCxyAJR9pbbTMggxzG2U2gPw1lJGy7Aajbv_ZEeY7eCTwXP5Uxb29ntrK0OfCWmnMszlohllqf3fCHOWcLzuUxXS7m4ZFchfHDOs3yeJ-wnky-vqE1qqEbAb4ee0G4Rvig2EBsEap3BFm3UkToLXQ0PZSkhRE2W7DtoW5240G8CfvYDCNGjjkdlXPHdThtHsT_0rd5AxECe7LBsoUG9I7MH5_EkYQXroizADc8GP1yzi1qbgDd_d8Lunh7fiue0651ynlrt90pwdWygxgZqbKCGBvKf-C8-Amq1</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Hochmair, M J</creator><creator>Weinlinger, C</creator><creator>Fabikan, H</creator><creator>Koger, R</creator><creator>Krenbeck, D</creator><creator>Huemer, F</creator><creator>Illini, O M</creator><creator>Kulaksiz, M</creator><creator>Valipour, A</creator><creator>Burghuber, O C</creator><general>Oxford University Press</general><scope/></search><sort><creationdate>20190401</creationdate><title>63PReal-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients</title><author>Hochmair, M J ; Weinlinger, C ; Fabikan, H ; Koger, R ; Krenbeck, D ; Huemer, F ; Illini, O M ; Kulaksiz, M ; Valipour, A ; Burghuber, O C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-oup_primary_10_1093_annonc_mdz071_0033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hochmair, M J</creatorcontrib><creatorcontrib>Weinlinger, C</creatorcontrib><creatorcontrib>Fabikan, H</creatorcontrib><creatorcontrib>Koger, R</creatorcontrib><creatorcontrib>Krenbeck, D</creatorcontrib><creatorcontrib>Huemer, F</creatorcontrib><creatorcontrib>Illini, O M</creatorcontrib><creatorcontrib>Kulaksiz, M</creatorcontrib><creatorcontrib>Valipour, A</creatorcontrib><creatorcontrib>Burghuber, O C</creatorcontrib><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hochmair, M J</au><au>Weinlinger, C</au><au>Fabikan, H</au><au>Koger, R</au><au>Krenbeck, D</au><au>Huemer, F</au><au>Illini, O M</au><au>Kulaksiz, M</au><au>Valipour, A</au><au>Burghuber, O C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>63PReal-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients</atitle><jtitle>Annals of oncology</jtitle><date>2019-04-01</date><risdate>2019</risdate><volume>30</volume><issue>Supplement_2</issue><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Oxford University Press</pub><doi>10.1093/annonc/mdz071.003</doi></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 2019-04, Vol.30 (Supplement_2)
issn 0923-7534
1569-8041
language eng
recordid cdi_oup_primary_10_1093_annonc_mdz071_003
source Alma/SFX Local Collection; EZB Electronic Journals Library
title 63PReal-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T17%3A08%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=63PReal-life%20experience%20with%20the%20implementation%20of%20DLL3%20staining%20and%20the%20subsequent%20treatment%20with%20rovalpituzumab%20tesirine%20in%20heavily%20pretreated%20SCLC%20patients&rft.jtitle=Annals%20of%20oncology&rft.au=Hochmair,%20M%20J&rft.date=2019-04-01&rft.volume=30&rft.issue=Supplement_2&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdz071.003&rft_dat=%3Coup%3E10.1093/annonc/mdz071.003%3C/oup%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/annonc/mdz071.003&rfr_iscdi=true